Global Internal Neurostimulation Devices Market - Industry Trends Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143144
- Pages: 225
-
Format:
Short Description:
Global Internal Neurostimulation Devices Market, By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider), Country (China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Germany, U.K., Italy, Spain, France, Switzerland, Belgium, Netherlands, Russia, Turkey and Rest of Europe, South Africa, UAE, Egypt, Saudi Arabia, Israel, Rest of the Middle East and Africa, U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Market Definition:
An internal neurostimulation device is a surgically placed device. It delivers mild electrical signals to the epidural space near your spine through one or more thin wires called leads. Neurostimulation provides pain relief by disrupting the pain signals traveling between the spinal cord and the brain.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
Market Segmentation:
The global internal neurostimulation devices market is categorized into product type and distribution channel.
On the basis of product type, the global internal neurostimulation devices market is segmented into spinal cord stimulation (SCS), deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation
On the basis of distribution channel, the global internal neurostimulation devices market is segmented into direct tender and third party service provider
Market Players:
Some key market players operating in the global internal neurostimulation devices market are listed below:
Medtronic
LivaNova PLC
Abbott
ONWARD
Sequana Medical NV
CIRTEC
Valencia Technologies
Nalu Medical, Inc.
NEVRO CORP.
Stimwave LLC
MicroTransponder Inc.
Newronika S.p.A.
Microsemi (a subsidiary of Microchip Technology Inc.)
Boston Scientific Corporation
Inspire Medical Systems, Inc
Integer Holdings Corporation
BlueWind Medical
Micro-Leads
Axonics, Inc.
Finetech Medical
ALEVA NEUROTHERAPEUTICS
GIMER Medical
OptoGenTech GmbH.
INBRAIN NEUROELECTRONICS
Mainstay Medical
Neuronano AB
Bionic Vision Technologies.
NEURIMPULSE s.r.l.
BIOINDUCTION
TABLE OF CONTENTS
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF GLOBAL INTERNAL NEUROSTIMULATION DEVICES MARKET 67
1.4 CURRENCY AND PRICING 70
1.5 LIMITATION 70
1.6 MARKETS COVERED 70
2 MARKET SEGMENTATION 75
2.1 MARKETS COVERED 75
2.2 GEOGRAPHIC SCOPE 76
2.3 YEARS CONSIDERED FOR THE STUDY 77
2.4 CURRENCY AND PRICING 77
2.5 RESEARCH METHODOLOGY 78
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 81
2.7 DBMR MARKET POSITION GRID 82
2.8 THE CATEGORY VS TIME GRID 84
2.9 SECONDARY SOURCES 85
2.10 ASSUMPTIONS 85
3 EXECUTIVE SUMMARY 86
4 PREMIUM INSIGHTS 89
4.1 PESTEL 91
4.2 PORTER'S FIVE FORCES MODEL 92
4.3 PIPELINE ANALYSIS FOR INTERNAL NEUROSTIMULATION DEVICES MARKET 93
5 REGULATIONS OF GLOBAL INTERNAL NEUROSTIMULATION DEVICES MARKET 95
6 EPIDEMIOLOGY OF DISEASES 97
6.1 INCIDENCE OF ISCHEMIA 97
6.2 INCIDENCE OF PARKINSON'S DISEASE 97
6.3 INCIDENCE OF FAILED BACK SYNDROME 98
6.4 INCIDENCE OF TREMOR 98
6.5 INCIDENCE OF DEPRESSION 99
6.6 INCIDENCE OF URINE INCONTINENCE 99
6.7 INCIDENCE OF FECAL INCONTINENCE 100
6.8 INCIDENCE RATE OF EPILEPSY 100
6.9 INCIDENCE OF GASTROPARESIS 101
6.10 PREVALENCE OF OBESITY 102
7 EPIDEMIOLOGY OF NEUROSTIMULATION PROCEDURES 104
7.1 NUMBER OF SPINAL CORD STIMULATION (SCS) PROCEDURES 104
7.1.1 NUMBER OF TEST PROCEDURES 104
7.1.2 NUMBER OF IMPLANTATION PROCEDURES 104
7.2 NUMBER OF DEEP BRAIN STIMULATION PROCEDURES 104
7.3 NUMBER OF VAGUS NERVE STIMULATION PROCEDURES 104
7.4 NUMBER OF SACRAL NEVER STIMULATION PROCEDURES 105
7.5 NUMBER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) PROCEDURES 105
7.6 NUMBER OF INTERMITTENT THETA BURST STIMULATION (ITBS) PROCEDURES 105
7.7 NUMBER OF TRANSCRANIAL DIRECT ELECTRICAL STIMULATION (TDCS) PROCEDURES 106
8 MARKET OVERVIEW 107
8.1 DRIVERS 109
8.1.1 RISE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS 109
8.1.2 DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY 110
8.1.3 INCREASED FUNDING FOR THE NEUROSTIMULATION DEVICES 110
8.1.4 TECHNOLOGICAL ADVANCEMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 110
8.1.5 RISE IN PRODUCT APPROVALS 111
8.2 RESTRAINTS 112
8.2.1 RISE IN COST OF THE DEEP BRAIN STIMULATION DEVICES 112
8.2.2 RISKS NOTICED WHILE USING THE INTERNAL NEUROSTIMULATION DEVICES 112
8.2.3 RISE IN PRODUCT RECALL 112
8.2.4 AVAILABILITY OF ALTERNATE IMAGING DIAGNOSTIC DEVICES 113
8.3 OPPORTUNITIES 113
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 113
8.3.2 RECENT PRODUCT DEVELOPMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 114
8.3.3 DEMAND FOR MINIMALLY INVASIVE SURGERY 114
8.4 CHALLENGES 115
8.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES 115
8.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS 115
9 GLOBAL INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE 116
9.1 OVERVIEW 117
9.2 SPINAL CORD STIMULATION 120
9.2.1 SPINAL CORD STIMULATION, BY TYPE 121
9.2.1.1 BATTERY 121
9.2.1.1.1 RECHARGEABLE 122
9.2.1.1.2 NON-RECHARGEABLE 122
9.2.1.2 LEAD 122
9.2.1.2.1 PERCUTANEOUS 123
9.2.1.2.2 PADDLE 123
9.2.2 SPINAL CORD STIMULATION, BY APPLICATION 123
9.2.2.1 ISCHEMIA 123
9.2.2.2 CHRONIC LOW BACK PAIN (CLBP) 123
9.2.2.3 DIABETIC NEUROPATHY 124
9.2.2.4 FAILED BACK SYNDROME 124
9.3 DEEP BRAIN STIMULATION 124
9.3.1 DEEP BRAIN STIMULATION, BY TYPE 125
9.3.1.1 SINGLE CHANNEL DEEP BRAIN STIMULATOR 126
9.3.1.2 DOUBLE CHANNEL DEEP BRAIN STIMULATOR 126
9.3.1.3 BATTERY 126
9.3.1.3.1 RECHARGEABLE 127
9.3.1.3.2 NON-RECHARGEABLE 127
9.3.1.4 LEAD 127
9.3.2 DEEP BRAIN STIMULATION, BY APPLICATION 127
9.3.2.1 PARKINSONS DISEASE 128
9.3.2.2 TREMOR 128
9.3.2.3 DEPRESSION 128
9.4 SACRAL NERVE STIMULATION 128
9.4.1 SACRAL NERVE STIMULATION, BY TYPE 129
9.4.1.1 BATTERY 130
9.4.1.2 LEAD 130
9.5 SACRAL NERVE STIMULATION, BY APPLICATION 130
9.5.1 URINE INCONTINENCE 130
9.5.2 FECAL INCONTINENCE 131
9.6 VAGUS NERVE STIMULATION 131
9.6.1 VAGUS NERVE STIMULATION, BY TYPE 132
9.6.1.1 BATTERY 133
9.6.1.2 LEAD 133
9.6.2 VAGUS NERVE STIMULATION, BY APPLICATION 133
9.6.2.1 EPILEPSY 133
9.6.2.2 OTHERS 133
9.7 GASTRIC ELECTRICAL STIMULATION 133
9.7.1 GASTRIC ELECTRICAL STIMULATION, BY TYPE 134
9.7.1.1 BATTERY 135
9.7.1.2 LEAD 135
9.7.2 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 135
9.7.2.1 GASTROPARESIS 136
9.7.2.2 OTHERS 136
10 GLOBAL INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL 137
10.1 OVERVIEW 138
10.2 DIRECT TENDER 140
10.3 THIRD PARTY PROVIDER 141
11 GLOBAL INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION 143
11.1 OVERVIEW 144
11.2 NORTH AMERICA 149
11.2.1 U.S. 161
11.2.2 CANADA 169
11.2.3 MEXICO 177
11.3 EUROPE 185
11.3.1 GERMANY 197
11.3.2 U.K. 205
11.3.3 ITALY 213
11.3.4 SPAIN 221
11.3.5 FRANCE 229
11.3.6 SWITZERLAND 237
11.3.7 BELGIUM 245
11.3.8 NETHERLANDS 253
11.3.9 RUSSIA 261
11.3.10 TURKEY 269
11.3.11 REST OF EUROPE 277
11.4 ASIA-PACIFIC 278
11.4.1 CHINA 290
11.4.2 JAPAN 299
11.4.3 SOUTH KOREA 307
11.4.4 INDIA 315
11.4.5 AUSTRALIA 323
11.4.6 SINGAPORE 331
11.4.7 THAILAND 339
11.4.8 MALAYSIA 347
11.4.9 INDONESIA 355
11.4.10 PHILIPPINES 363
11.4.11 REST OF ASIA-PACIFIC 371
11.5 SOUTH AMERICA 372
11.5.1 BRAZIL 385
11.5.2 ARGENTINA 393
11.5.3 COLOMBIA 401
11.5.4 REST OF SOUTH AMERICA 409
11.6 MIDDLE EAST AND AFRICA 410
11.6.1 SOUTH AFRICA 423
11.6.2 U.A.E. 431
11.6.3 EGYPT 439
11.6.4 SAUDI ARABIA 447
11.6.5 ISRAEL 455
11.6.6 REST OF MIDDLE EAST AND AFRICA 463
12 GLOBAL INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY LANDSCAPE 464
12.1 COMPANY SHARE ANALYSIS: GLOBAL 464
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 465
12.3 COMPANY SHARE ANALYSIS: EUROPE 466
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 467
13 SWOT ANALYSIS 468
14 COMPANY PROFILE 469
14.1 MEDTRONIC (2021) 469
14.1.1 COMPANY SNAPSHOT 469
14.1.2 REVENUE ANALYSIS 469
14.1.3 COMPANY SHARE ANALYSIS 470
14.1.4 PRODUCT PORTFOLIO 470
14.1.5 RECENT DEVELOPMENTS 471
14.2 BOSTON SCIENTIFIC CORPORATION (2021) 472
14.2.1 COMPANY SNAPSHOT 472
14.2.2 REVENUE ANALYSIS 473
14.2.3 COMPANY SHARE ANALYSIS 473
14.2.4 PRODUCT PORTFOLIO 474
14.2.5 RECENT DEVELOPMENTS 474
14.3 ABBOTT (2021) 476
14.3.1 COMPANY SNAPSHOT 476
14.3.2 REVENUE ANALYSIS 476
14.3.3 COMPANY SHARE ANALYSIS 477
14.3.4 PRODUCT PORTFOLIO 477
14.3.5 RECENT DEVELOPMENTS 478
14.4 LIVANOVA PLC (2021) 479
14.4.1 COMPANY SNAPSHOT 479
14.4.2 REVENUE ANALYSIS 479
14.4.3 COMPANY SHARE ANALYSIS 480
14.4.4 PRODUCT PORTFOLIO 480
14.4.5 RECENT DEVELOPMENTS 480
14.5 NEVRO CORP. (2021) 482
14.5.1 COMPANY SNAPSHOT 482
14.5.2 REVENUE ANALYSIS 482
14.5.3 COMPANY SHARE ANALYSIS 483
14.5.4 PRODUCT PORTFOLIO 483
14.5.5 RECENT DEVELOPMENTS 484
14.6 AXONICS, INC. 485
14.6.1 COMPANY SNAPSHOT 485
14.6.2 REVENUE ANALYSIS 485
14.6.3 PRODUCT PORTFOLIO 486
14.6.4 RECENT DEVELOPMENTS 486
14.7 ALEVA NEUROTHERAPEUTICS 487
14.7.1 COMPANY SNAPSHOT 487
14.7.2 PRODUCT PORTFOLIO 487
14.7.3 RECENT DEVELOPMENTS 487
14.8 BIONIC VISION TECHNOLOGIES. 488
14.8.1 COMPANY SNAPSHOT 488
14.8.2 PRODUCT PORTFOLIO 488
14.8.3 RECENT DEVELOPMENTS 488
14.9 BLUEWIND MEDICAL 489
14.9.1 COMPANY SNAPSHOT 489
14.9.2 PRODUCT PORTFOLIO 489
14.9.3 RECENT DEVELOPMENTS 489
14.10 BIOINDUCTION 490
14.10.1 COMPANY SNAPSHOT 490
14.10.2 PRODUCT PORTFOLIO 490
14.10.3 RECENT DEVELOPMENT 490
14.11 CIRTEC 491
14.11.1 COMPANY SNAPSHOT 491
14.11.2 PRODUCT PORTFOLIO 491
14.11.3 RECENT DEVELOPMENTS 492
14.12 FINETECH MEDICAL 493
14.12.1 COMPANY SNAPSHOT 493
14.12.2 PRODUCT PORTFOLIO 493
14.12.3 RECENT DEVELOPMENTS 493
14.13 GIMER MEDICAL 494
14.13.1 COMPANY SNAPSHOT 494
14.13.2 PRODUCT PORTFOLIO 494
14.13.3 RECENT DEVELOPMENTS 494
14.14 INSPIRE MEDICAL SYSTEMS, INC. 495
14.14.1 COMPANY SNAPSHOT 495
14.14.2 REVENUE ANALYSIS 495
14.14.3 PRODUCT PORTFOLIO 496
14.14.4 RECENT DEVELOPMENTS 496
14.15 INTEGER HOLDINGS CORPORATION 497
14.15.1 COMPANY SNAPSHOT 497
14.15.2 REVENUE ANALYSIS 497
14.15.3 PRODUCT PORTFOLIO 498
14.15.4 RECENT DEVELOPMENT 498
14.16 INBRAIN NEUROELECTRONICS 499
14.16.1 COMPANY SNAPSHOT 499
14.16.2 PRODUCT PORTFOLIO 499
14.16.3 RECENT DEVELOPMENT 499
14.17 MAINSTAY MEDICAL 500
14.17.1 COMPANY SNAPSHOT 500
14.17.2 REVENUE ANALYSIS 500
14.17.3 PRODUCT PORTFOLIO 501
14.17.4 RECENT DEVELOPMENTS 501
14.18 MICROSEMI (A WHOLLY OWNDED SUBSIDIARY OF MICROCHIP TECHNOLOGY INC.) 502
14.18.1 COMPANY SNAPSHOT 502
14.18.2 REVENUE ANALYSIS 502
14.18.3 PRODUCT PORTFOLIO 503
14.18.4 RECENT DEVELOPMENTS 503
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
